Eppdata is uniquely positioned to support the lifecycle of clinical studies with information technology development and domain specific medical expertise.
Weβve just enrolled the 100th patient in the #TECNO trial πΏπ
A huge thank you to all sites, teams, and patients for making this progress possible π
Congratulations: Great engineering and impressive results. TICI double read with full end-to-end traceability. Proud to be part of your journey! @Fie0815@RaulNogueiraMD
Preliminary results from the MARRS pivotal IDE trial were presented at @SNISinfo, highlighting Millipede88 performance in acute ischemic stroke:
πΉ 77% First Pass Effect for M1 occlusions
πΉ 99% Delivery success
πΉ Promising safety profile
bit.ly/3Gu2mFT@Wayne_Perfuze
ERASER is the first mechanical thrombectomy study with a primary endpoint based on predictive analytics enabling intraindividual virtual comparisons.
This innovative study design paves the way for faster, more reliable evaluations in clinical trials.
#Stroke#NeuroIntervention